Event driven focus on Labcorp Holdings stock

Labcorp Holdings (LH) has been in focus after launching its AI powered MyLabcorp app, stepping up efforts in specialty testing, and receiving an analyst upgrade tied to a stronger earnings outlook.

Recent gains, including a 1-day share price return of 1.63% and 7-day share price return of 3.81%, suggest improving momentum around the MyLabcorp launch, specialty testing push, and the analyst upgrade. These returns are set against a 1-year total shareholder return of 8.33% and a 3-year total shareholder return of 45.10%.

If Labcorp's AI and lab focus has your attention, this is a good moment to widen your search and see which other healthcare AI opportunities stand out in our 34 healthcare AI stocks

With a recent 90 day share price decline of 8.89%, a stated intrinsic discount of 50.97%, and a 19.31% gap to the average analyst target, the key question is whether this signals value or whether the stock already reflects future growth.

Most Popular Narrative: 16.2% Undervalued

Labcorp's most followed valuation narrative points to a fair value of $310.06 per share versus the last close at $259.93, setting up a clear gap for investors to assess.

The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

Want to see what is driving this valuation gap? The narrative focuses on steadier revenue expansion, higher margins, and a future earnings multiple that assumes investors continue to pay a premium for this testing and AI mix.

Result: Fair Value of $310.06 (UNDERVALUED)

However, you should also keep an eye on potential hits to margins from tariffs or regulatory shifts, as well as on pressure from competitors when key lab contracts renew.

Next Steps

With both concerns and positives in this story, now is a good time to move quickly, review the data yourself, and weigh the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not stop at a single stock when you can quickly scan fresh opportunities tailored to different goals, risk levels, and income needs using the Simply Wall Street Screener.

• Jump on potential value opportunities by reviewing companies that currently appear cheap on quality and fundamentals in the 49 high quality undervalued stocks.
• Target resilient portfolio anchors by zeroing in on companies with strong finances and low-risk profiles through the 67 resilient stocks with low risk scores.
• Spot early standouts before the crowd by checking the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.